1. Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

2. Disclosure Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

3. Outline Slide Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

4. Background Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

5. Primary Objective Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

6. Secondary Objectives Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

7. Design Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

8. Final OPTIMIZE-2 study design Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

9. Demographics, Baseline Characteristics Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

10. SRE Rate (Primary Endpoint) Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

11. Time-to-First SRE Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

12. Skeletal Morbidity Rate (SMR) Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

13. Safety Summary Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

14. Bone Markers Change from Baseline Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

15. Conclusions Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

16. Back Ups Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

17. Number of Infusions Prior to Study Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

18. Renal Adverse Events Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting